NFKB2 (Ab-866) Antibody

What are the recommended applications for NFKB2 (Ab-866) Antibody?

NFKB2 (Ab-866) Antibody has been validated for multiple research applications including Western Blotting (WB), Immunohistochemistry (IHC), Enzyme-Linked Immunosorbent Assay (ELISA), and Immunofluorescence (IF). For optimal results, the recommended dilutions are: WB (1:500-1:1000), IHC (1:50-1:200), and IF (1:100-1:200). The antibody detects endogenous levels of total NFkB-p100 protein and can be used across human, mouse, and rat samples, making it versatile for comparative studies across these species .

How should NFKB2 (Ab-866) Antibody be stored and handled?

For optimal preservation of antibody activity, store NFKB2 (Ab-866) Antibody at -20°C or -80°C immediately upon receipt. Avoid repeated freeze-thaw cycles as these can significantly degrade antibody performance. The antibody is supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide, and 50% glycerol . When working with the antibody, maintain sterile conditions and use proper laboratory safety practices, particularly noting the presence of sodium azide in the formulation.

What is the epitope recognized by NFKB2 (Ab-866) Antibody?

NFKB2 (Ab-866) Antibody recognizes a specific peptide sequence around amino acids 864-868 (E-D-S-A-Y) derived from Human NFkB-p100 . This epitope is located in the C-terminal region of the protein, which is significant as this region plays a crucial role in the phosphorylation and processing of p100 to p52 - a key step in the noncanonical NF-κB signaling pathway . Understanding this specific epitope helps researchers interpret results, particularly when comparing with other antibodies targeting different regions of the NFKB2 protein.

How can I validate the specificity of NFKB2 (Ab-866) Antibody in my experimental system?

To validate antibody specificity in your experimental system, implement the following methodological approach: (1) Include positive controls using cell lines known to express NFKB2, such as HT29 cells; (2) Perform blocking experiments with the immunizing peptide (as demonstrated in the IHC images with human breast carcinoma tissue); (3) Use NFKB2 knockout or knockdown samples as negative controls; (4) Compare staining patterns across multiple applications (WB, IHC, IF) to ensure consistent detection of the expected molecular weight and cellular localization patterns ; (5) Validate results with an alternative antibody targeting a different epitope of NFKB2 to confirm findings .

How can NFKB2 (Ab-866) Antibody be used to study the noncanonical NF-κB pathway?

For comprehensive analysis of the noncanonical NF-κB pathway using NFKB2 (Ab-866) Antibody, design experiments that examine the processing of p100 to p52. This antibody detects total NFkB-p100 protein, allowing researchers to monitor both the precursor (p100) and processed form (p52) by Western blotting . When studying this pathway: (1) Use stimuli known to activate noncanonical signaling (e.g., CD40L, BAFF, or lymphotoxin-β); (2) Perform time-course experiments to track p100 processing kinetics; (3) Combine with phospho-specific antibodies targeting key phosphorylation sites (such as Ser866, Ser870) that regulate processing ; (4) Correlate with nuclear translocation of p52 using nuclear/cytoplasmic fractionation followed by Western blotting or immunofluorescence; (5) Consider co-immunoprecipitation studies to examine interactions with pathway components like NIK (NF-κB inducing kinase) .

What considerations should be made when using NFKB2 (Ab-866) Antibody to study NFKB2 mutations associated with immunodeficiency?

When investigating NFKB2 mutations associated with immunodeficiency disorders like CVID (Common Variable Immunodeficiency), several methodological considerations are critical: (1) Since the antibody recognizes an epitope near amino acids 864-868, mutations affecting this region may alter antibody binding - verify that your mutation of interest does not directly affect the epitope ; (2) Design experiments to assess p100 processing defects by comparing wild-type and mutant NFKB2 in overexpression systems or patient-derived cells ; (3) Complement Western blotting with immunofluorescence to assess nuclear translocation defects; (4) Consider including functional readouts such as target gene expression analysis (e.g., CXCL13) to correlate processing defects with downstream functional outcomes ; (5) When studying patient samples, include age and sex-matched controls and consider the heterozygous nature of many reported NFKB2 mutations .

How can I design experiments to investigate the relationship between NFKB2 phosphorylation and protein processing?

To investigate NFKB2 phosphorylation and its relationship to processing, implement the following approach: (1) Use NFKB2 (Ab-866) Antibody alongside phospho-specific antibodies targeting Ser866 and Ser870 to monitor total and phosphorylated forms simultaneously ; (2) Perform overexpression studies with wild-type NFKB2 and phosphorylation site mutants (S866A, S870A) using plasmid preparation methods ; (3) Include NIK co-expression to enhance phosphorylation, as NIK triggers this process; (4) Use time-course studies after pathway stimulation to correlate phosphorylation with processing kinetics; (5) Apply pharmacological inhibitors of the pathway to confirm specificity; (6) Consider using lambda phosphatase treatment as a control to demonstrate phosphorylation-specific detection . This multi-faceted approach will provide comprehensive insights into how phosphorylation regulates NFKB2 processing.

What are common technical challenges when using NFKB2 (Ab-866) Antibody for Western blotting?

When using NFKB2 (Ab-866) Antibody for Western blotting, researchers may encounter several technical challenges: (1) Difficulty detecting both p100 and p52 forms - ensure sufficient gel resolution by using 8-10% acrylamide gels with extended run times; (2) High background - optimize blocking conditions (try 5% BSA instead of milk for phospho-specific detection) and increase washing stringency; (3) Weak signal - consider longer exposure times, enhanced chemiluminescence substrates, or signal amplification systems; (4) Sample preparation issues - use phosphatase inhibitors to preserve phosphorylation status and optimize lysis buffers for nuclear protein extraction; (5) Loading control selection - choose appropriate controls based on your experimental design (nuclear proteins like Lamin B1 may be more appropriate than cytoplasmic housekeeping proteins when studying nuclear translocation) . Methodologically, always include positive control lysates (such as HT29 cells) alongside experimental samples.

How can I optimize immunohistochemistry protocols with NFKB2 (Ab-866) Antibody?

To optimize immunohistochemistry protocols with NFKB2 (Ab-866) Antibody, follow this methodological approach: (1) Antigen retrieval optimization - test both heat-induced epitope retrieval methods (citrate buffer pH 6.0 and EDTA buffer pH 9.0) to determine optimal conditions; (2) Antibody concentration titration - begin with the recommended 1:50-1:200 dilution range and adjust based on signal-to-noise ratio ; (3) Incubation conditions - compare room temperature (1-2 hours) versus 4°C overnight incubation; (4) Detection system selection - choose between ABC, polymer-based, or tyramide signal amplification systems based on desired sensitivity; (5) Counterstain optimization - adjust hematoxylin intensity to maintain nuclear detail without obscuring positive signals; (6) Implement proper controls - include positive control tissues (human breast carcinoma), negative controls (omitting primary antibody), and peptide competition controls as shown in the reference images .

What are the best practices for using NFKB2 (Ab-866) Antibody in immunofluorescence applications?

For optimal immunofluorescence results with NFKB2 (Ab-866) Antibody, implement these methodological best practices: (1) Fixation method optimization - compare paraformaldehyde fixation with methanol fixation as demonstrated in HeLa cells ; (2) Permeabilization conditions - adjust detergent concentration and incubation time to balance cell integrity with antibody accessibility; (3) Blocking optimization - use 3-5% BSA or normal serum matched to secondary antibody host; (4) Primary antibody dilution - begin with the recommended range (1:100-1:200) and optimize based on signal intensity and background ; (5) Secondary antibody selection - choose fluorophores compatible with your microscopy setup and other channels in multi-color experiments; (6) Nuclear counterstaining - use DAPI or Hoechst at optimized concentrations to visualize nuclei without overwhelming NFKB2 signal; (7) Include appropriate controls and consider co-staining with markers of cellular compartments to assess NFKB2 localization.

How should researchers interpret NFKB2 (Ab-866) Antibody results in the context of noncanonical NF-κB pathway activation?

When interpreting results from NFKB2 (Ab-866) Antibody in the context of noncanonical NF-κB pathway activation, apply the following analytical framework: (1) In Western blotting, assess the ratio of p52 to p100 as an indicator of processing efficiency - increased p52:p100 ratio suggests pathway activation; (2) In immunofluorescence, evaluate nuclear translocation of NFKB2 - cytoplasmic staining represents primarily p100, while nuclear accumulation indicates processed p52 ; (3) Consider the kinetics of the noncanonical pathway, which typically shows delayed and sustained activation compared to the rapid and transient canonical pathway ; (4) Integrate results with other pathway components - NIK stabilization and IKKα activation should precede p100 processing ; (5) Connect observations to functional outcomes by assessing target gene expression changes; (6) In disease contexts (e.g., CVID), interpret results in relation to known mutation effects - C-terminal mutations often impair processing, resulting in p100 accumulation and reduced p52 nuclear translocation .

How can researchers quantitatively analyze NFKB2 processing in Western blot experiments?

To quantitatively analyze NFKB2 processing in Western blot experiments, implement this methodological approach: (1) Densitometric analysis - use image analysis software to measure band intensities of both p100 and p52 forms; (2) Calculate processing ratio - determine the p52:p100 ratio as a measure of processing efficiency across different experimental conditions; (3) Normalization strategy - normalize to appropriate loading controls, considering that p100 is primarily cytoplasmic while p52 translocates to the nucleus; (4) Statistical analysis - apply appropriate statistical tests when comparing processing across multiple conditions or time points; (5) Dynamic range consideration - ensure exposure times capture both p100 and p52 without saturation; (6) Replicate analysis - perform at least three biological replicates to account for variability; (7) Presentation format - consider presenting data in both representative blot images and quantitative graphs showing processing ratios with statistical analysis .

What complementary assays should be performed alongside NFKB2 (Ab-866) Antibody experiments?

To develop a comprehensive understanding of NFKB2 biology, complement NFKB2 (Ab-866) Antibody experiments with these methodological approaches: (1) Functional readouts - measure expression of noncanonical NF-κB target genes (e.g., CXCL13) using qPCR as described in the literature ; (2) Pathway component analysis - assess NIK levels, IKKα phosphorylation, and other upstream regulators ; (3) Protein-protein interaction studies - perform co-immunoprecipitation to examine interactions between NFKB2 and pathway regulators; (4) Cellular phenotyping - particularly in immune cells, correlate NFKB2 processing with functional outcomes like proliferation, cytokine production, or B cell differentiation ; (5) Subcellular fractionation - quantitatively assess nuclear translocation of p52; (6) Chromatin immunoprecipitation (ChIP) - determine binding of p52 to target gene promoters; (7) Phospho-specific detection - use antibodies targeting key phosphorylation sites (e.g., Ser866, Ser870) to monitor the specific modifications that trigger processing .

How can NFKB2 (Ab-866) Antibody be used to study NFKB2-associated immunodeficiency disorders?

When using NFKB2 (Ab-866) Antibody to study NFKB2-associated immunodeficiency disorders, implement the following research strategy: (1) Patient-control comparisons - analyze NFKB2 processing in primary cells from patients with NFKB2 mutations versus healthy controls; (2) Mutation modeling - create cell line models expressing wild-type or mutant NFKB2 (particularly C-terminal mutations) and assess processing using the antibody ; (3) Functional correlations - connect processing defects to B cell development, antibody production, and other immune parameters relevant to CVID ; (4) Pathway intervention studies - test whether enhancing noncanonical pathway activity can overcome processing defects; (5) Biomarker development - evaluate whether p100/p52 ratios correlate with disease severity or treatment response; (6) When analyzing patient samples, consider the heterozygous nature of most NFKB2 mutations and how this may affect antibody binding and result interpretation .

What methodological approaches can be used to study the role of NFKB2 in NK cell function?

To investigate NFKB2's role in NK cell function, implement the following methodological approaches: (1) NK cell isolation and culture - obtain primary NK cells from peripheral blood or use NK cell lines; (2) Phenotypic analysis - use NFKB2 (Ab-866) Antibody in combination with flow cytometry to assess expression levels across NK cell developmental stages; (3) Functional assays - correlate NFKB2 processing with NK cell cytotoxicity assays, particularly in contexts like CMV infection where NK cell defects have been reported in patients with NFKB2 mutations ; (4) Stimulation experiments - assess how different NK-activating signals affect NFKB2 processing; (5) Genetic approaches - use siRNA knockdown or CRISPR-Cas9 editing of NFKB2 to directly assess its role in NK function; (6) Patient-derived cells - compare NK cells from patients with NFKB2 mutations to controls, focusing on both signaling and functional outcomes; (7) Cytokine response - measure how NFKB2 processing affects production of NK-derived cytokines.

How can NFKB2 (Ab-866) Antibody contribute to research on inflammatory disorders?

To leverage NFKB2 (Ab-866) Antibody in inflammatory disorder research, implement these methodological approaches: (1) Time-course analysis - track changes in NFKB2 processing during disease progression or following inflammatory stimuli; (2) Cell-type specific analysis - use immunohistochemistry to identify which cell populations show altered NFKB2 processing in inflammatory contexts ; (3) Intervention studies - assess how anti-inflammatory treatments affect NFKB2 processing and nuclear translocation; (4) Feedback regulation assessment - investigate how negative regulators (e.g., deubiquitinating enzymes like A20 and CYLD) affect NFKB2 in inflammatory settings ; (5) Cytokine response correlation - connect NFKB2 processing patterns with production of specific inflammatory mediators; (6) Animal model validation - use the cross-reactivity of the antibody with mouse and rat samples to validate findings across species and experimental models ; (7) Therapeutic target evaluation - use the antibody to assess potential intervention points in the noncanonical pathway for treatment of inflammatory conditions.